Biosceptre is at the forefront of cancer treatment innovation, focusing on the development of a multiple-targeted universal CAR T system designed to enhance therapeutic outcomes for a diverse range of malignancies. Central to their approach is the BRiDGECAR™ system, which integrates the nfP2X7-targeted universal CAR T with multiple targeted antibodies. This pioneering technology aims to create a next-generation cancer therapy capable of addressing various forms of cancer, including both liquid and solid tumors. Biosceptre's commitment to advancing these therapies is underscored by their ongoing research programs, which are geared towards delivering best-in-class treatment options for cancer patients globally.

In addition to their therapeutic innovations, Biosceptre has established a strategic partnership with the University of Technology Sydney (UTS) to enhance the capabilities of the Biologics Innovation Facility (BIF). This collaboration aims to accelerate analytical and process development within the Australian biopharmaceutical sector, particularly in the realm of antibody characterization and development. The BIF, notable for its GMP-ready cleanrooms and single-use manufacturing technology, serves as a critical resource for Biosceptre's targeted therapeutic and immune-oncology programs, thereby contributing to the broader landscape of biopharmaceutical research and development in Australia and Southeast Asia.

United Kingdom

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Cancer

Digestive System Diseases

Hematologic Diseases

Immune System Diseases

Lymphatic Diseases

Biosceptre

Acute myeloid leukemia

Follicular lymphoma

Multiple myeloma

BRiDGECAR™-based therapy

Biologics

CAR-T Immunotherapy

Cell Therapies

Europe - West

Antibodies

Peptide Therapies

Small Molecule Pharmaceuticals

Diagnostics

Therapeutic

Biosceptre

Company Details